GB9915204D0 - Vaccine - Google Patents

Vaccine

Info

Publication number
GB9915204D0
GB9915204D0 GBGB9915204.3A GB9915204A GB9915204D0 GB 9915204 D0 GB9915204 D0 GB 9915204D0 GB 9915204 A GB9915204 A GB 9915204A GB 9915204 D0 GB9915204 D0 GB 9915204D0
Authority
GB
United Kingdom
Prior art keywords
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9915204.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to GBGB9915204.3A priority Critical patent/GB9915204D0/en
Publication of GB9915204D0 publication Critical patent/GB9915204D0/en
Priority to AU59777/00A priority patent/AU5977700A/en
Priority to CA002376926A priority patent/CA2376926A1/en
Priority to EP00945810A priority patent/EP1198243A2/en
Priority to PCT/EP2000/005841 priority patent/WO2001000231A2/en
Priority to HK02107137.7A priority patent/HK1047034A1/en
Priority to US10/789,758 priority patent/US20050002958A1/en
Priority to US11/934,814 priority patent/US20080131464A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB9915204.3A 1999-06-29 1999-06-29 Vaccine Ceased GB9915204D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB9915204.3A GB9915204D0 (en) 1999-06-29 1999-06-29 Vaccine
AU59777/00A AU5977700A (en) 1999-06-29 2000-06-23 Vaccines
CA002376926A CA2376926A1 (en) 1999-06-29 2000-06-23 Use of cpg as an adjuvant for malaria vaccine
EP00945810A EP1198243A2 (en) 1999-06-29 2000-06-23 Use of cpg as an adjuvant for malaria vaccine
PCT/EP2000/005841 WO2001000231A2 (en) 1999-06-29 2000-06-23 Use of cpg as an adjuvant for malaria vaccine
HK02107137.7A HK1047034A1 (en) 1999-06-29 2002-09-26 Use of cpg as an adjuvant for malaria vaccine
US10/789,758 US20050002958A1 (en) 1999-06-29 2004-02-27 Vaccines
US11/934,814 US20080131464A1 (en) 1999-06-29 2007-11-05 Vaccines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9915204.3A GB9915204D0 (en) 1999-06-29 1999-06-29 Vaccine

Publications (1)

Publication Number Publication Date
GB9915204D0 true GB9915204D0 (en) 1999-09-01

Family

ID=10856286

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9915204.3A Ceased GB9915204D0 (en) 1999-06-29 1999-06-29 Vaccine

Country Status (6)

Country Link
EP (1) EP1198243A2 (en)
AU (1) AU5977700A (en)
CA (1) CA2376926A1 (en)
GB (1) GB9915204D0 (en)
HK (1) HK1047034A1 (en)
WO (1) WO2001000231A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69932717T2 (en) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
US6855322B2 (en) * 2001-01-26 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Isolation and purification of P. falciparum merozoite protein-142 vaccine
EP1414490A1 (en) * 2001-08-10 2004-05-06 Dynavax Technologies Corporation Immunomodulatory oligonucleotide formulations and methods for use thereof
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US20070104726A1 (en) * 2002-08-14 2007-05-10 Avidis Sa Multimeric complexes of antigens and adjuvants
JP4199988B2 (en) * 2002-11-14 2008-12-24 大日本印刷株式会社 Decorative sheet
EA016417B1 (en) 2006-09-07 2012-04-30 Глаксосмитклайн Байолоджикалс С.А. Method of making vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010152A1 (en) * 1991-11-16 1993-05-27 Smithkline Beecham Biologicals S.A. HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG
AU713040B2 (en) * 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (en) * 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Use of nucleic acids containing non-methylated CpG dinucleotide in combination with alum as adjuvants
ES2298316T3 (en) * 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. WATER OIL EMULSIONS CONTAINING SAPONINS.
EP1126876B1 (en) * 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
DK1187629T3 (en) * 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide

Also Published As

Publication number Publication date
CA2376926A1 (en) 2001-01-04
HK1047034A1 (en) 2003-02-07
WO2001000231A3 (en) 2001-07-05
EP1198243A2 (en) 2002-04-24
AU5977700A (en) 2001-01-31
WO2001000231A2 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
IL145044A0 (en) Vaccine
HUS1300072I1 (en) Vaccine
HUP0202885A3 (en) Vaccines
HK1105581A1 (en) Vaccine composition
EP1083926A4 (en) Vaccine
GB9910812D0 (en) Vaccine composition
GB9915204D0 (en) Vaccine
GB9901254D0 (en) Vaccines
GB0027072D0 (en) Vaccine
GB9906437D0 (en) Vaccine
GB9913327D0 (en) Vaccine
MXPA01010701A (en) Vaccine.
GB9930591D0 (en) Component for vaccine
GB9909072D0 (en) Vaccine
GB9930585D0 (en) Component for vaccine
GB9917144D0 (en) Vaccine
GB9922700D0 (en) Vaccine
GB9925619D0 (en) Vaccine
GB9925618D0 (en) Vaccine
GB9904405D0 (en) Vaccine
GB9904408D0 (en) Vaccine
GB9922703D0 (en) Vaccine
GB9904412D0 (en) Vaccine
GB9922701D0 (en) Vaccine
GB9905511D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)